Top

Open Access 28-09-2024 | Human Immunodeficiency Virus | Substantive Review

A Systematic Review and Narrative Synthesis of Factors Affecting Pre-exposure Prophylaxis Willingness Among Black Women for HIV Prevention

Authors: Alexis Sims Haynes, Christine Markham, Vanessa Schick, Robert Suchting, Nivedhitha Parthasarathy, Sumaita Choudhury, Mandy J. Hill

Published in: AIDS and Behavior

Abstract

Pre-exposure prophylaxis (PrEP) can significantly reduce human immunodeficiency virus (HIV) transmission among Black women in the United States (U.S.), a group disproportionately affected by HIV. However, PrEP uptake in this HIV-vulnerable population is low. This review analyzes the factors influencing Black women's PrEP willingness using the Behavioral Model for Vulnerable Populations (BMVP). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Population, Intervention, Comparison, Outcome, Study Design (PICOS) framework, we conducted a systematic literature search and selected 24 peer-reviewed studies on PrEP willingness. Narrative synthesis revealed a heterogeneous landscape of the determinants affecting PrEP willingness among Black women, categorized into three main domains. Predisposing demographic and social factors included younger age, unmarried status, higher education, sexual or gender minority identity, trust in healthcare providers, and perceived HIV risk. Predisposing behavioral factors included condomless sex, multiple partners, and engagement in sex work. Socioeconomic status, health insurance, healthcare access, support systems, and structural challenges were identified as enabling factors influencing Black women’s PrEP willingness. Finally, the perceived need domain and health-related factors influencing the perceived need for PrEP included a history of sexually transmitted infections (STI), intimate partner violence (IPV), and birth control interference. This study emphasizes the complexity of the barriers and facilitators of PrEP uptake and, thus, the need for tailored interventions and health strategies to promote its use. Addressing the interconnected individual, interpersonal, and structural determinants of PrEP access is crucial for improving PrEP willingness and thereby advancing health equity in this population.

Available only for authorised users

Sullivan PS, Satcher Johnson A, Pembleton ES, et al. Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. The Lancet. 2021;397(10279):1095–06. https://doi.org/10.1016/S0140-6736(21)00395-0.CrossRef

CDC. HIV surveillance | reports| resource library | HIV/AIDS | CDC. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Updated 2024.

CDC. Black americans and HIV/AIDS: The basics The Henry J. Kaiser Family Foundation Web site. https://www.kff.org/hivaids/fact-sheet/black-americans-and-hivaids-the-basics/. Updated 2018.

Murnane PM, Celum C, Mugo N, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS. 2013;27(13):2155–60. https://doi.org/10.1097/QAD.0b013e3283629037.CrossRefPubMed

Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8(2):94–103. https://doi.org/10.1007/s11904-011-0078-4.CrossRefPubMedPubMedCentral

Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the united states. Ann Epidemiol. 2017;27(4):238–43. https://doi.org/10.1016/j.annepidem.2017.02.003.CrossRefPubMedPubMedCentral

Ransome Y, Bogart LM, Nunn AS, Mayer KH, Sadler KR, Ojikutu BO. Faith leaders’ messaging is essential to enhance HIV prevention among black Americans: results from the 2016 national survey on HIV in the black community (NSHBC). BMC Public Health. 2018. https://doi.org/10.1186/s12889-018-6301-0.CrossRefPubMedPubMedCentral

Wingood GM, Dunkle K, Camp C, et al. Racial differences and correlates of potential adoption of preexposure prophylaxis: results of a national survey. J Acquir Immune Defic Syndr. 2013;63(1):S95-101. https://doi.org/10.1097/QAI.0b013e3182920126.CrossRefPubMedPubMedCentral

CDC. HIV and black/African American people in the U.S. | fact sheets | newsroom | NCHHSTP | centesrs for disease control and prevention. https://www.cdc.gov/nchhstp/newsroom/fact-sheetss/hiv/black-african-american-factsheet.html. Updated 2022.

10.

Cooper HL, Caruso B, Barham T, et al. Partner incarceration and African American women’s sexual relationships and risk: a longitudinal qualitative study. J Urban Health. 2015;92(3):527–47. https://doi.org/10.1007/s11524-015-9941-8.CrossRefPubMedPubMedCentral

11.

Garfinkel DB, Alexander KA, McDonald-Mosley R, Willie TC, Decker MR. Predictors of HIV-related risk perception and PrEP acceptability among young adult female family planning patients. AIDS care. 2017;29(6):751–8. https://doi.org/10.1080/09540121.2016.1234679.CrossRefPubMed

12.

Calabrese SK, Willie TC, Galvao RW, et al. Current US guidelines for prescribing HIV pre-exposure prophylaxis (PrEP) disqualify many women who are at risk and motivated to use PrEP. J Acquir Immune Defic Syndr. 2019;81(4):395–405. https://doi.org/10.1097/QAI.0000000000002042.CrossRefPubMedPubMedCentral

13.

Rosenthal L, Earnshaw VA, Lewis JB, et al. Discrimination and sexual risk among young urban pregnant women of color. Health Psychol. 2014;33(1):3–10. https://doi.org/10.1037/a0032502.CrossRefPubMedPubMedCentral

14.

Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22. https://doi.org/10.1056/NEJMoa1202614.CrossRefPubMedPubMedCentral

15.

Flash C, Stone VE, Mitty J, Mimiaga MJ, Hall KT, Krakower D. Acceptability of oral or vaginal HIV pre-exposure prophylaxis among at-risk black women in the United States. 2012.

16.

Paxton KC, Williams JK, Bolden S, Guzman Y, Harawa NT. HIV risk behaviors among African American women with at-risk male partners. J AIDS Clin Res. 2013;4(7):221. https://doi.org/10.4172/2155-6113.1000221.PMID:24455447;PMCID:PMC3895435.CrossRefPubMedPubMedCentral

17.

Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. https://doi.org/10.1056/NEJMoa1108524.CrossRefPubMedPubMedCentral

18.

Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. https://doi.org/10.1056/NEJMoa1011205.CrossRefPubMedPubMedCentral

19.

Jiang J, Yang X, Ye L, et al. Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials. PLoS One. 2014. https://doi.org/10.1371/journal.pone.0087674.CrossRefPubMedPubMedCentral

20.

Mujugira A, Baeten JM, Donnell D, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS ONE. 2011. https://doi.org/10.1371/journal.pone.0025828.CrossRefPubMedPubMedCentral

21.

Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14(11):1055–64. https://doi.org/10.1016/S1473-3099(14)70937-5.CrossRefPubMedPubMedCentral

22.

Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in bangkok, thailand (the bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381(9883):2083–90. https://doi.org/10.1016/S0140-6736(13)61127-7.CrossRef

23.

Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012;7(2):99–105. https://doi.org/10.1097/COH.0b013e32834f5cf2.CrossRefPubMedPubMedCentral

24.

Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–8. https://doi.org/10.1097/QAI.0000000000000172.CrossRefPubMedPubMedCentral

25.

Murnane PM, Heffron R, Ronald A, et al. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. Aids. 2014;28(12):1825–30. https://doi.org/10.1097/QAD.0000000000000290.CrossRefPubMed

26.

Heffron R, Mugo N, Were E, et al. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. AIDS. 2014;28(18):2771–6. https://doi.org/10.1097/QAD.0000000000000493.CrossRefPubMed

27.

Pilgrim NA, Evans TM, Czarnogorski M. A layer plus approach to implementation research and collaboration for long-acting injectable preexposure prophylaxis for HIV prevention. Health Prom Prac. 2022;23(6):912–5. https://doi.org/10.1177/15248399211053584.CrossRef

28.

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach, 2nd ed. https://www.who.int/publications-detail-redirect/9789241549684. Updated 2016.

29.

UNAIDS. Global AIDS strategy 2021–2026 — end inequalities. end AIDS. https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDS-strategy. Updated 2021.

30.

Baldwin A, Light B, Allison WE. Pre-exposure prophylaxis (PrEP) for HIV infection in cisgender and transgender women in the US: a narrative review of the literature. Arch Sex Behav. 2021;50(4):1713–28. https://doi.org/10.1007/s10508-020-01903-8.CrossRefPubMedPubMedCentral

31.

Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9. https://doi.org/10.1016/j.annepidem.2018.06.005.CrossRefPubMedPubMedCentral

32.

Thornhill J, Orkin C. Long-acting injectable HIV therapies: the next frontier. Curr Opin HIV AIDS. 2021;34(1):8–15. https://doi.org/10.1097/QCO.0000000000000701.CrossRef

33.

Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agent. 2021. https://doi.org/10.1016/j.ijantimicag.2020.106220.CrossRef

34.

FDA. FDA approves first injectable treatment for HIV pre-exposure prevention. https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention. Updated 2021.

35.

Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608. https://doi.org/10.1056/NEJMoa2101016.CrossRefPubMedPubMedCentral

36.

Poteat T, Reisner SL, Radix A. HIV epidemics among transgender women. Curr Opin HIV AIDS. 2014;9(2):168–73. https://doi.org/10.1097/COH.0000000000000030.CrossRefPubMedPubMedCentral

37.

Irie WC, Calabrese SK, Patel RR, Mayer KH, Geng EH, Marcus JL. Preferences for HIV preexposure prophylaxis products among black women in the US. AIDS Behav. 2022;26(7):2212–23. https://doi.org/10.1007/s10461-021-03571-8.CrossRefPubMedPubMedCentral

38.

Meyers K, Golub SA. Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities. Curr Opin HIV AIDS. 2015;10(4):290–5. https://doi.org/10.1097/COH.0000000000000159.CrossRefPubMedPubMedCentral

39.

Lambert CC, Marrazzo J, Amico KR, Mugavero MJ, Elopre L. PrEParing women to prevent HIV: an integrated theoretical framework to PrEP black women in the United States. J Assoc Nurs AIDS Care. 2018;29(6):835–48. https://doi.org/10.1016/j.jana.2018.03.005.CrossRef

40.

D’Avanzo PA, Bass SB, Brajuha J, et al. Medical mistrust and PrEP perceptions among transgender women: a cluster analysis. Behav Med. 2019;45(2):143–52. https://doi.org/10.1080/08964289.2019.1585325.CrossRefPubMed

41.

Huang YA, Zhu W, Smith DK, Harris N, Hoover KW. HIV preexposure prophylaxis, by race and ethnicity–United States, 2014–2016. MMWR Morb Mortal Wkly Rep. 2018;67(41):1147–50. https://doi.org/10.15585/mmwr.mm6741a3.CrossRefPubMedPubMedCentral

42.

van Epps P, Maier M, Lund B, et al. Medication adherence in a nationwide cohort of veterans initiating pre-exposure prophylaxis (PrEP) to prevent HIV infection. J Acquir Immune Defic Syndr. 2018;77(3):272–8. https://doi.org/10.1097/QAI.0000000000001598.CrossRefPubMed

43.

The POWER Study Team, Eaton LA, Matthews DD, et al. A multi-US city assessment of awareness and uptake of pre-exposure prophylaxis (PrEP) for HIV prevention among black men and transgender women who have sex with men. Prev Sci. 2017;18(5):505–16. https://doi.org/10.1007/s11121-017-0756-6.CrossRefPubMedCentral

44.

Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K. FTC/TDF (truvada) for HIV pre-exposure prophylaxis (PrEP) utilization in the united states:2013–2015. 2016.

45.

Smith DK, Van Handel M, Grey JA. By race/ethnicity, blacks had the highest number needing PrEP in the US in 2015. 2018.

46.

Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18. https://doi.org/10.1056/NEJMoa1402269.CrossRefPubMedPubMedCentral

47.

Young I, Li J, McDaid L. Awareness and willingness to use HIV pre-exposure prophylaxis amongst gay and bisexual men in Scotland: implications for biomedical HIV prevention. PLoS One. 2013. https://doi.org/10.1371/journal.pone.0064038.CrossRefPubMedPubMedCentral

48.

Wu H, Mendoza MCB, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United states, 2010–2014. CLINID. 2017;64(2):144–9. https://doi.org/10.1093/cid/ciw701.CrossRef

49.

Raifman JR, Schwartz SR, Sosnowy CD, et al. Brief report: pre-exposure prophylaxis awareness and use among cisgender women at a sexually transmitted disease clinic. J Acquir Immune Defic Syndr. 2019;80(1):36–9. https://doi.org/10.1097/QAI.0000000000001879.CrossRefPubMedPubMedCentral

50.

Zhang C, McMahon J, Simmons J, Brown LL, Nash R, Liu Y. Suboptimal HIV pre-exposure prophylaxis awareness and willingness to use among women who use drugs in the united states: a systematic review and meta-analysis. AIDS Behav. 2019;23(10):2641–53. https://doi.org/10.1007/s10461-019-02573-x.CrossRefPubMedPubMedCentral

51.

Klein H, Elifson KW, Sterk CE. “At risk” women who think that they have no chance of getting HIV: Self-assessed perceived risks. Women Health. 2003;38(2):47–63. https://doi.org/10.1300/J013v38n02_04.CrossRefPubMed

52.

Pringle K, Merchant RC, Clark MA. Is self-perceived HIV risk congruent with reported HIV risk among traditionally lower HIV risk and prevalence adult emergency department patients? Implications for HIV testing. AIDS Patient Care STDS. 2013;27(10):573–84. https://doi.org/10.1089/apc.2013.0013.CrossRefPubMedPubMedCentral

53.

Collier KL, Colarossi LG, Sanders K. Raising awareness of pre-exposure prophylaxis (PrEP) among women in New York city: community and provider perspectives. J Health Commun. 2017;22(3):183–9. https://doi.org/10.1080/10810730.2016.1261969.CrossRefPubMed

54.

Goparaju L, Praschan NC, Warren-Jeanpiere L, Experton LS, Young MA, Kassaye S. Stigma, partners, providers, and costs: potential barriers to PrEP uptake among US women. J AIDS Clin Res. 2017. https://doi.org/10.4172/2155-6113.1000730.CrossRefPubMedPubMedCentral

55.

Ojikutu BO, Mayer KH. Hidden in plain sight: Identifying women living in the United States who could benefit from HIV preexposure prophylaxis. J Infect Dis. 2020;222(9):1428–31. https://doi.org/10.1093/infdis/jiz416.CrossRefPubMed

56.

Rael CT, Martinez M, Giguere R, et al. Barriers and facilitators to oral PrEP use among transgender women in New York city. AIDS Behav. 2018;22(11):3627–36. https://doi.org/10.1007/s10461-018-2102-9.CrossRefPubMedPubMedCentral

57.

Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS care. 2018;30(10):1282–9. https://doi.org/10.1080/09540121.2018.1447079.CrossRefPubMedPubMedCentral

58.

Salazar LF, Crosby RA, Jones J, Kota K, Hill B, Masyn KE. Contextual, experiential, and behavioral risk factors associated with HIV status: a descriptive analysis of transgender women residing in Atlanta Georgia. Int J STD AIDS. 2017;28(11):1059–66. https://doi.org/10.1177/0956462416686722.CrossRefPubMed

59.

Sevelius JM, Keatley J, Calma N, Arnold E. “I am not a man”: trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11(7–8):1060–75. https://doi.org/10.1080/17441692.2016.1154085.CrossRefPubMedPubMedCentral

60.

Marks SJ, Merchant RC, Clark MA, et al. Potential healthcare insurance and provider barriers to pre-exposure prophylaxis utilization among young men who have sex with men. AIDS Patient Care STDS. 2017;31(11):470–8. https://doi.org/10.1089/apc.2017.0171.CrossRefPubMedPubMedCentral

61.

Ndugga N, Artiga S, Orgera K. Disparities in health and health care: 5 key questions and answers. https://www.kff.org/racial-equity-and-health-policy/issue-brief/disparities-in-health-and-health-care-5-key-question-and-answers/. Updated 2023.

62.

Patel AS, Goparaju L, Sales JM, et al. Brief report: PrEP eligibility among at-risk women in the southern United States: associated factors, awareness, and acceptability. J Acquir Immune Defic Syndr. 2019;80(5):527–32. https://doi.org/10.1097/QAI.0000000000001950.CrossRefPubMedPubMedCentral

63.

Schwartz J, Grimm J. PrEP on twitter: information, barriers, and stigma. Health Commun. 2017;32(4):509–16. https://doi.org/10.1080/10410236.2016.1140271.CrossRefPubMed

64.

65.

Kadushin G. Home health care utilization: a review of the research for social work. Health Social Work. 2004;29(3):219–44. https://doi.org/10.1093/hsw/29.3.219.CrossRefPubMed

66.

Hochhausen L, Le H, Perry DF. Community-based mental health service utilization among low-income latina immigrants. Commun Ment Health J. 2011;47(1):14–23. https://doi.org/10.1007/s10597-009-9253-0.CrossRef

67.

Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22. https://doi.org/10.1016/S1473-3099(12)70315-8.CrossRefPubMed

68.

Bronfenbrenner U. The ecology of human development: experiments by nature and design. Cambridge: Harvard University Press; 1979.CrossRef

69.

Calabrese SK, Underhill K. How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize “Truvada whores.” Am J Public Health. 2015;105(10):1960–4. https://doi.org/10.2105/AJPH.2015.302816.CrossRefPubMedPubMedCentral

70.

Krakower DS, Mayer KH. The role of healthcare providers in the roll out of preexposure prophylaxis. Curr Opin HIV AIDS. 2016;11(1):41–8. https://doi.org/10.1097/COH.0000000000000206.CrossRefPubMedPubMedCentral

71.

Ojikutu BO, Bogart LM, Mayer KH, Stopka TJ, Sullivan PS, Ransome Y. Spatial access and willingness to use pre-exposure prophylaxis among black/african american individuals in the united states: cross-sectional survey. JMIR Public Health Surveill. 2019. https://doi.org/10.2196/12405.CrossRefPubMedPubMedCentral

72.

Parkhurst JO. Structural approaches for prevention of sexually transmitted HIV in general populations: definitions and an operational approach. J Int AIDS Soc. 2014. https://doi.org/10.7448/IAS.17.1.19052.CrossRefPubMedPubMedCentral

73.

Poteat T, Wirtz AL, Radix A, et al. HIV risk and preventive interventions in transgender women sex workers. The Lancet. 2015;385(9964):274–86. https://doi.org/10.1016/S0140-6736(14)60833-3.CrossRef

74.

Ransome Y, Kawachi I, Braunstein S, Nash D. Structural inequalities drive late HIV diagnosis: the role of black racial concentration, income inequality, socioeconomic deprivation, and HIV testing. Health & Place. 2016;42:148–58. https://doi.org/10.1016/j.healthplace.2016.09.004.CrossRef

75.

Ransome Y, Kawachi I, Dean LT. Neighborhood social capital in relation to late HIV diagnosis, linkage to HIV care, and HIV care engagement. AIDS Behav. 2017;21(3):891–904. https://doi.org/10.1007/s10461-016-1581-9.CrossRefPubMed

76.

Poteat T, Wirtz A, Malik M, et al. A gap between willingness and uptake: findings from mixed methods research on HIV prevention among black and latina transgender women. J Acquir Immune Defic Syndr. 2019;82(2):131–40. https://doi.org/10.1097/QAI.0000000000002112.CrossRefPubMedPubMedCentral

77.

Kelley CF, Kahle E, Siegler A, et al. Applying a PrEP continuum of care for men who have sex with men in atlanta, georgia. Clin Infect Dis. 2015;61(10):1590–7. https://doi.org/10.1093/cid/civ664.CrossRefPubMedPubMedCentral

78.

Calabrese SK. Interpreting gaps along the preexposure prophylaxis cascade and addressing vulnerabilities to stigma. Am J Public Health. 2018;108(10):1284–6. https://doi.org/10.2105/AJPH.2018.304656.CrossRefPubMedPubMedCentral

79.

Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, et al. Defining the HIV pre-exposure prophylaxis care continuum. AIDS. 2017;31(5):731–4. https://doi.org/10.1097/QAD.0000000000001385.CrossRefPubMed

80.

Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS. 2013;27(10):553–9. https://doi.org/10.1089/apc.2013.0173.CrossRefPubMed

81.

Koren DE, Nichols JS, Simoncini GM. HIV pre-exposure prophylaxis and women: survey of the knowledge, attitudes, and beliefs in an urban obstetrics/gynecology clinic. AIDS Patient Care STDS. 2018;32(12):490–4. https://doi.org/10.1089/apc.2018.0030.CrossRefPubMed

82.

Ojikutu BO, Bogart LM, Higgins-Biddle M, et al. Facilitators and barriers to pre-exposure prophylaxis (PrEP) use among black individuals in the United States: results from the national survey on HIV in the black community (NSHBC). AIDS Behav. 2018;22(11):3576–87. https://doi.org/10.1007/s10461-018-2067-8.CrossRefPubMedPubMedCentral

83.

Doblecki-Lewis S, Lester L, Schwartz B, Collins C, Johnson R, Kobetz E. HIV risk and awareness and interest in pre-exposure and post-exposure prophylaxis among sheltered women in Miami. Int J STD AIDS. 2016;27(10):873–81. https://doi.org/10.1177/0956462415601304.CrossRefPubMed

84.

Flash CA, Adegboyega OO, Yu X, et al. Correlates of linkage to HIV pre-exposure prophylaxis (PrEP) among HIV testing clients. J Acquir Immune Defic Syndr. 2018;77(4):365–72. https://doi.org/10.1097/QAI.0000000000001605.CrossRefPubMedPubMedCentral

85.

Khawcharoenporn T, Kendrick S, Smith K. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic. AIDS Patient Care STDS. 2012;26(4):222–33. https://doi.org/10.1089/apc.2011.0202.CrossRefPubMed

86.

Peng B, Yang X, Zhang Y, et al. Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China. HIV AIDS (Auckl). 2012;4:149–58. https://doi.org/10.2147/HIV.S33445.CrossRefPubMed

87.

Martin M, Vanichseni S, Suntharasamai P, et al. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok tenofovir study. Lancet HIV. 2017;4(2):e59-66. https://doi.org/10.1016/S2352-3018(16)30207-7.CrossRefPubMed

88.

Walters SM, Kral AH, Simpson KA, Wenger L, Bluthenthal RN. HIV pre-exposure prophylaxis prevention awareness, willingness, and perceived barriers among people who inject drugs in Los Angeles and San Francisco, CA, 2016–2018. Subst Use Misuse. 2020;55(14):2409–19. https://doi.org/10.1080/10826084.2020.1823419.CrossRefPubMedPubMedCentral

89.

Hill MJ, Heads AM, Suchting R, Stotts AL. A survey with interventional components delivered on tablet devices versus usual care to increase pre-exposure prophylaxis uptake among cisgender black women: a pilot randomized controlled trial. BMC Infect Dis. 2023. https://doi.org/10.1186/s12879-023-08019-z.CrossRefPubMedPubMedCentral

90.

Kwakwa HA, Bessias S, Sturgis D, et al. Attitudes toward HIV pre-exposure prophylaxis in a united states urban clinic population. AIDS Behav. 2016;20(7):1443–50. https://doi.org/10.1007/s10461-016-1407-9.CrossRefPubMed

91.

Wilson EC, Jin H, Liu A, Raymond HF. Knowledge, indications and willingness to take pre-exposure prophylaxis among transwomen in San Francisco 2013. PLoS One. 2015. https://doi.org/10.1371/journal.pone.0128971.CrossRefPubMedPubMedCentral

92.

Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10.CrossRefPubMed

93.

Gelberg L, Andersen RM, Leake BD. The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34(6):1273–302.PubMedPubMedCentral

94.

Cohen SE, Vittinghoff E, Bacon O, et al. High interest in pre-exposure prophylaxis among men who have sex with men at risk for HIV-infection: Baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439–48. https://doi.org/10.1097/QAI.0000000000000479.CrossRefPubMedPubMedCentral

95.

Goedel WC, Halkitis PN, Greene RE, Duncan DT. Correlates of awareness of and willingness to use pre-exposure prophylaxis (PrEP) in gay, bisexual, and other men who have sex with men who use geosocial-networking smartphone applications in New York city. AIDS Behav. 2016;20(7):1435–42. https://doi.org/10.1007/s10461-016-1353-6.CrossRefPubMed

96.

Hoagland B, De Boni RB, Moreira RI, et al. Awareness and willingness to use pre-exposure prophylaxis (PrEP) among men who have sex with men and transgender women in Brazil. AIDS Behav. 2017;21(5):1278–87. https://doi.org/10.1007/s10461-016-1516-5.CrossRefPubMed

97.

Hood JE, Buskin SE, Dombrowski JC, et al. Dramatic increase in preexposure prophylaxis use among MSM in washington state. AIDS. 2016;30(3):515–9. https://doi.org/10.1097/QAD.0000000000000937.CrossRefPubMed

98.

King HL, Keller SB, Giancola MA, et al. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE study). AIDS Behav. 2014;18(9):1722–5. https://doi.org/10.1007/s10461-014-0845-5.CrossRefPubMedPubMedCentral

99.

Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: a review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2014;18(2):195–216. https://doi.org/10.1007/s10461-013-0560-7.CrossRefPubMed

100.

Ferrer L, Folch C, Fernandez-Davila P, et al. Awareness of pre-exposure prophylaxis for HIV, willingness to use it and potential barriers or facilitators to uptake among men who have sex with men in spain. AIDS Behav. 2016;20(7):1423–33. https://doi.org/10.1007/s10461-016-1379-9.CrossRefPubMed

101.

Kuo I, Olsen H, Patrick R, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington. DC Drug Alcohol Depend. 2016;164:8–13. https://doi.org/10.1016/j.drugalcdep.2016.02.044.CrossRefPubMed

102.

Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014;18(9):1694–700. https://doi.org/10.1007/s10461-014-0778-z.CrossRefPubMedPubMedCentral

103.

Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. Stigma and conspiracy beliefs related to pre-exposure prophylaxis (PrEP) and interest in using PrEP among black and white men and transgender women who have sex with men. AIDS Behav. 2017;21(5):1236–46. https://doi.org/10.1007/s10461-017-1690-0.CrossRefPubMedPubMedCentral

104.

Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in new york city. AIDS Patient Care STDS. 2013;27(4):248–54. https://doi.org/10.1089/apc.2012.0419.CrossRefPubMedPubMedCentral

105.

Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015. https://doi.org/10.1186/2046-4053-4-1.CrossRefPubMedPubMedCentral

106.

Durai S. Building blocks: the art and science of searching the literature. Indian J Cont Nurs Educ. 2021. https://doi.org/10.4103/IJCN.IJCN_140_20.CrossRef

107.

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016. https://doi.org/10.1186/s13643-016-0384-4.CrossRefPubMedPubMedCentral

108.

Higgins J, Morgan R, Rooney A, et al. Risk of bias tools - ROBINS-E tool. https://www.riskofbias.info/welcome/robins-e-tool. Updated 2023.

109.

Ryan R, Hill S. How to GRADE the quality of the evidence. 2016. http://cccrg.cochrane.org/author-resources.

110.

Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94. https://doi.org/10.1016/j.jclinepi.2010.04.026.CrossRefPubMed

111.

Popay J, Roberts H, Sowden A, et al. Guidance on the conduct of narrative synthesis in systematic reviews: A product from the ESRC methods programme.; 2006.

112.

Lathlean J. Qualitative methods for health research J judith green qualitative methods for health research and NickiThorogood sage 280 £19.99076194771X. Nurse Res. 2005;13(2):91–2.CrossRef

113.

Strauss A, Corbin JM. Basics of qualitative research: grounded theory procedures and technique. Thousand Oaks: Sage Publications; 1990.

114.

Bryman A. Social research methods. 5th ed. Oxford: Oxford University Press; 2012.

115.

Charmaz K, Lincoln Y, Denzin N. Grounded theory: Objectivist and constructivist methods. In: Handbook of qualitative research. ; 2000:509–535. https://www.researchgate.net/publication/272787056_Grounded_Theory_Objectivist_and_Constructivist_Methods.

116.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https://doi.org/10.1136/bmj.n71.CrossRefPubMedPubMedCentral

117.

McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Method. 2021;12(1):55–61. https://doi.org/10.1002/jrsm.1411.CrossRef

118.

Cochrane handbook for systematic reviews of interventions. Repr. with corr ed. Chichester, West Sussex: John Wiley & Sons; 2009:649.

119.

Pollock A, Farmer SE, Brady MC, et al. An algorithm was developed to assign GRADE levels of evidence to comparisons within systematic reviews. J Clin Epidemiol. 2016;70:106–10. https://doi.org/10.1016/j.jclinepi.2015.08.013.CrossRefPubMedPubMedCentral

120.

Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67. https://doi.org/10.1007/s10461-016-1625-1.CrossRefPubMedPubMedCentral

121.

Nunn A, Parker S, McCoy K, et al. African American clergy perspectives about the HIV care continuum: results from a qualitative study in Jackson Mississippi. Ethn Dis. 2018. https://doi.org/10.18865/ed.28.2.85.CrossRefPubMedPubMedCentral

122.

Van Der Straten A, Stadler J, Luecke E, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, south Africa. J Int AIDS Soc. 2014. https://doi.org/10.7448/IAS.17.3.19146.CrossRefPubMedPubMedCentral

123.

Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84. https://doi.org/10.1001/jamainternmed.2015.4683.CrossRefPubMedPubMedCentral

124.

Willie TC, Monger M, Nunn A, et al. “PrEP’s just to secure you like insurance”: a qualitative study on HIV pre-exposure prophylaxis (PrEP) adherence and retention among black cisgender women in Mississippi. BMC Infect Dis. 2021. https://doi.org/10.1186/s12879-021-06786-1.CrossRefPubMedPubMedCentral

125.

Taggart T, Liang Y, Pina P, Albritton T. Awareness of and willingness to use PrEP among black and latinx adolescents residing in higher prevalence areas in the United States. PLoS ONE. 2020. https://doi.org/10.1371/journal.pone.0234821.CrossRefPubMedPubMedCentral

126.

Sophus AI, Mitchell JW, Barroso J, Sales JM. Factors associated with planned future use of PrEP in the next 3 months and likelihood to use PrEP among black cisgender HIV-negative women in texas. AIDS Behav. 2024;28(1):72–92. https://doi.org/10.1007/s10461-023-04188-9.CrossRefPubMed

127.

Tekeste M, Hull S, Dovidio JF, et al. Differences in medical mistrust between black and white women: implications for patient-provider communication about PrEP. AIDS Behav. 2019;23(7):1737–48. https://doi.org/10.1007/s10461-018-2283-2.CrossRefPubMedPubMedCentral

128.

Oldenburg CE, Mitty JA, Biello KB, et al. Differences in attitudes about HIV pre-exposure prophylaxis use among stimulant versus alcohol using men who have sex with men. AIDS Behav. 2016;20(7):1451–60. https://doi.org/10.1007/s10461-015-1226-4.CrossRefPubMedPubMedCentral

129.

Walters SM, Frank D, Van Ham B, et al. PrEP care continuum engagement among persons who inject drugs: rural and urban differences in stigma and social infrastructure. AIDS Behav. 2022;26(4):1308–20. https://doi.org/10.1007/s10461-021-03488-2.CrossRefPubMed

130.

Roth AM, Aumaier BL, Felsher MA, et al. An exploration of factors impacting preexposure prophylaxis eligibility and access among syringe exchange users. Sexual Trans Dis. 2018;45(4):217–21. https://doi.org/10.1097/OLQ.0000000000000728.CrossRef

131.

Smith DK, Van Handel M, Huggins R. Estimated coverage to address financial barriers to HIV preexposure prophylaxis among persons with indications for its use, United States 2015. J Acquir Immune Defic Syndr. 2017;76(5):465–72. https://doi.org/10.1097/QAI.0000000000001532.CrossRefPubMedPubMedCentral

132.

Park CJ, Taylor TN, Gutierrez NR, Zingman BS, Blackstock OJ. Pathways to HIV pre-exposure prophylaxis among women prescribed PrEP at an urban sexual health clinic. J Acquir Immune Defic Syndr. 2019;30(3):321–9. https://doi.org/10.1097/JNC.0000000000000070.CrossRef

133.

Corneli A, Perry B, McKenna K, et al. Participants’ explanations for nonadherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr. 2016;71(4):452–61. https://doi.org/10.1097/QAI.0000000000000880.CrossRefPubMed

134.

Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review. Adv Ther. 2020;37(5):1778–811. https://doi.org/10.1007/s12325-020-01295-0.CrossRefPubMedPubMedCentral

135.

Irie WC, Mahone A, Nakka R, Ghebremichael M. Factors associated with comfort discussing PrEP with healthcare providers among black cisgender women. TropicalMed. 2023. https://doi.org/10.3390/tropicalmed8090436.CrossRef

136.

Bazzi AR, Drainoni M, Biancarelli DL, et al. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions. BMC Public Health. 2019. https://doi.org/10.1186/s12889-018-6314-8.CrossRefPubMedPubMedCentral

137.

Underhill K, Guthrie KM, Colleran C, Calabrese SK, Operario D, Mayer KH. Temporal fluctuations in behavior, perceived HIV risk, and willingness to use pre-exposure prophylaxis (PrEP). Arch Sex Behav. 2018;47(7):2109–21. https://doi.org/10.1007/s10508-017-1100-8.CrossRefPubMedPubMedCentral

138.

NIAID National Institute of Allergy and Infectious Diseases. National Institutes of Health. NIH Statement on Preliminary Efficacy Results of Twice-Yearly Lenacapavir for HIV Prevention in Cisgender Women. 2024. https://www.niaid.nih.gov/news-events/nih-statement-preliminary-efficacy-results-twice-yearly-lenacapavir-hiv-prevention

139.

Hammer JH, Vogel DL. Assessing the utility of the willingness/prototype model in predicting help-seeking decisions. J Couns Psychol. 2013;60(1):83–97. https://doi.org/10.1037/a0030449.CrossRefPubMed

140.

Rivis A, Sheeran P, Armitage CJ. Augmenting the theory of planned behaviour with the prototype/willingness model: predictive validity of actor versus abstainer prototypes for adolescents’ health-protective and health-risk intentions. Br J Health Psychol. 2006;11(3):483–500. https://doi.org/10.1348/135910705X70327.CrossRefPubMed

141.

Pomery EA, Gibbons FX, Reis-Bergan M, Gerrard M. From willingness to intention: experience moderates the shift from reactive to reasoned behavior. Pers Soc Psychol Bull. 2009;35(7):894–908. https://doi.org/10.1177/0146167209335166.CrossRefPubMedPubMedCentral

Title: A Systematic Review and Narrative Synthesis of Factors Affecting Pre-exposure Prophylaxis Willingness Among Black Women for HIV Prevention
Authors: Alexis Sims Haynes
Christine Markham
Vanessa Schick
Robert Suchting
Nivedhitha Parthasarathy
Sumaita Choudhury
Mandy J. Hill
Publication date: 28-09-2024
Publisher: Springer US
Keyword: Human Immunodeficiency Virus
Published in: AIDS and Behavior
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-024-04491-z

Keynote webinar | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on menopause

Keynote webinar | Spotlight on adolescent vaping

Keynote webinar | Spotlight on modern management of frailty

A quick guide to ECGs

At a glance: The STEP trials